Table 4

Effect of the cost-sharing change on adherence to essential medications

AntiplateletBeta-blockersACEI/ARBStatins
Pensioners group versus control groupLevel change (%)−1.790 (1.24)−1.021 (0.97)−6.792 (6.35)**−8.293 (5.61)**
Slope change (%)0.004 (0.50)0.000 (0.03)0.023 (3.84)**0.031 (3.67)**
Time to counterfactual adherence rates for pensioners (months)15.417.9>20.718.4
R 2 0.970.960.920.97
Middle-income to high-income group versus control groupLevel change (%)−1.120 (0.54)−2.295 (1.41)0.066 (0.04)−7.806 (3.57)**
Slope change (%)0.010 (0.83)0.028 (3.03)**−0.001 (0.17)0.044 (3.50)**
Time to counterfactual adherence rates for middle-income to high-income population (months)12.412.011.713.6
R 2 0.730.680.640.76
n=312
Antiplatelet, acetyl salicylic acid; ACEI/ARB, ACE inhibitors and angiotensin II receptor blockers.
t-ratios in parentheses *p<0.05; **p<0.01.